Hamilton Lane Advisors’s Theriva Biologics TOVX Stock Holding History

Hamilton Lane Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3	Closed	–	–	52
2018 Q2	$0	Hold	3	–	–	﹤0.01%	47
2018 Q1	$0	Hold	3	–	–	﹤0.01%	51
2017 Q4	$12K	Hold	3	–	–	0.01%	55
2017 Q3	$22K	Hold	3	–	–	0.02%	50
2017 Q2	$13K	Hold	3	–	–	0.01%	51
2017 Q1	$15K	Hold	3	–	–	0.01%	59
2016 Q4	$18K	Hold	3	–	–	0.01%	63
2016 Q3	$41K	Hold	3	–	–	0.02%	60
2016 Q2	$52K	Hold	3	–	–	0.03%	57
2016 Q1	$56K	Hold	3	–	–	0.03%	55
2015 Q4	$55K	Hold	3	–	–	0.02%	48
2015 Q3	$54K	Hold	3	–	–	0.03%	48
2015 Q2	$68K	Hold	3	–	–	0.03%	60
2015 Q1	$52K	Hold	3	–	–	0.02%	51
2014 Q4	$35K	Buy	+3	New	+$40.3K	0.01%	51
2014 Q3	–	Sell	-3	Closed	-$41K	–	66
2014 Q2	$41K	Hold	3	–	–	0.01%	56
2014 Q1	$61K	Hold	3	–	–	0.02%	66
2013 Q4	$36K	Hold	3	–	–	0.02%	49
2013 Q3	$40K	Hold	3	–	–	0.02%	49
2013 Q2	$41K	Buy	+3	New	+$41K	0.02%	58

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Hamilton Lane Advisors's TOVX Position: Q3 2018 in Review

Hamilton Lane Advisors sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 3 shares.

Hamilton Lane Advisors first reported a position in TOVX in Q2 2013 and held it in 20 quarters. The position peaked at $68K in Q2 2015. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

Hamilton Lane Advisors reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
Hamilton Lane Advisors sold 3 Theriva Biologics shares in Q3 2018.
Hamilton Lane Advisors first reported a position in Theriva Biologics in Q2 2013 and held it in 20 quarters.
Hamilton Lane Advisors's Theriva Biologics position peaked at $68K in Q2 2015.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Hamilton Lane Advisors's 13F filing for Q3 2018, filed 16 Oct 2018.